Dementia and Alzheimer Disease

New phase 2 data reveals AR1001's potential as a cognitive enhancer and disease-modifying therapy for mild to moderate Alzheimer's disease.

New data reveals lecanemab's long-term benefits for early Alzheimer's patients, showcasing improved cognitive outcomes and promising safety profiles over four years.

New findings reveal racial disparities in Alzheimer’s trial eligibility, highlighting higher screen failure rates among Black participants in the Auτonomy study.

The senior data scientist at Linus Health discussed how acoustic and speech-based metrics can be used to capture subtle cognitive signals during neuropsychological assessments. [WATCH TIME: 6 minutes]

AAV2-BDNF gene therapy shows promise in reversing cognitive decline in early Alzheimer's, enhancing neuronal function and safety in initial trials.

The chief scientific officer at Neurogen Biomarking outlined a novel home-based diagnostic model that can accelerate detection of early AD through biomarker profiling. [WATCH TIME: 5 minutes]

The associate professor in the Department of Psychiatry at McGill University discussed the strengths and limitations of PET and blood biomarkers in identifying early Alzheimer disease.

Phase 2 VIVA-MIND study shows varoglutamstat is safe for early Alzheimer’s patients but fails to improve cognitive outcomes.

A new analysis revealed structural brain differences among patients with breast cancer who experienced chemotherapy-associated cognitive impairment following anthracycline-taxane treatment.

New research reveals nicotinamide riboside supplementation enhances hippocampal perfusion in adults with mild cognitive impairment, but memory performance remains unchanged.

The associate professor of neurology at Icahn School of Medicine at Mount Sinai discussed the clinical and scientific advantages of blood-based biomarkers over imaging for Alzheimer disease. [WATCH TIME: 5 minutes]

At AAIC 2025, the chief medical officer at CND Life Sciences discussed recent progress in detecting neurodegenerative diseases earlier using tools like the Syn-One Test. [WATCH TIME: 3 minutes]

Although the FDA-approved therapies lecanemab and donanemab both slow progression in early Alzheimer disease, a new study presented at AAIC 2025 highlighted differences in their safety profiles.

New research revealed that structured lifestyle programs could significantly enhance cognitive function in older adults at risk of decline, outperforming self-guided interventions.

In a new study presented at AAIC 2025, findings showed that walking significantly slowed cognitive decline in APOE ε4 carriers, especially among Black and White women.

A new study presented at AAIC 2025 suggested that combination therapy with cardiovascular medications was associated with slower cognitive decline in older adults.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple sclerosis diets.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 25, 2025.

The AHEAD 3-45 Study is currently assessing lecanemab asymptomatic stage of Alzheimer disease to assess whether the therapy can slow biomarker changes or cognitive decline at the earliest phases.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

Findings show that apathy affects more than half of individuals with LBD, challenging assumptions that it emerges only in later stages and underscoring the need for targeted screening tools and intervention strategies.

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.